EGFR and neoplasm: Finally, with the intention to initiate in the near future a phase I dose-limiting toxicity trial combining (ruxolitinib + an ERBB1/2/4 inhibitor) in patients at Massey Cancer Center, we performed additional multiplex antibody array analyses on tumor material from the (ruxolitinib + afatinib) BT474 tumor growth experiment to identify possible response biomarkers in tumor cells that had survived and re-grown after drug treatment.